3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
145
Carcinoma, Intraductal, Noninfiltrating
12
Breast Carcinoma In Situ
10
Neoplasm Metastasis
9
Breast Neoplasms, Male
9
Neoplasms
5
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Gliosarcoma
3
Glioma
3
Glioblastoma
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Ductal, Breast
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Sarcoma
2
Oligodendroglioma
2
Multiple Endocrine Neoplasia Type 1
2
Liver Neoplasms
2
Hot Flashes
2
Glioma, Subependymal
2
Fibroadenoma
2
Ependymoma
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Astrocytoma
2
Thyroid Neoplasms
1
Interventions
Everolimus
17
lutetium Lu 177 dotatate
7
Octreotide
7
pasireotide
6
lanreotide
6
gallium Ga 68 dotatate
5
Temozolomide
5
Sunitinib
5
Positron Emission Tomography Computed Tomography
5
surufatinib
4
pembrolizumab
4
Sorafenib
4
Data Collection
4
Carboplatin
4
3-Iodobenzylguanidine
4
Positron-Emission Tomography
3
Nivolumab
3
Etoposide
3
Capecitabine
3
90Y-octreotide, DOTA-Tyr(3)-
3
pentetreotide
2
pazopanib
2
lenvatinib
2
fosbretabulin
2
fluorodopa F 18
2
cabozantinib
2
avelumab
2
arginyllysine
2
Single Photon Emission Computed Tomography Computed Tomography
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroendocrine Tumors
×
Tamoxifen
×
Clear all
NCT03870399
2024-05-06
HORMONET
AC Camargo Cancer Center
Phase 2
Completed
23 enrolled